Literature DB >> 15182268

Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides.

Sakae Homma1, Hiroshi Matsushita, Koichiro Nakata.   

Abstract

OBJECTIVE: The association of pulmonary fibrosis (PF) with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitides has not been well documented. The aim of this study was to assess the clinicopathological characteristics of PF in patients who tested positive for MPO-ANCA.
METHODOLOGY: In this study, 31 patients (17 males and 14 females; mean age, 69 years) diagnosed as having PF with positive MPO-ANCA levels ranging from 10 to 840 EU with a mean of 112.5 EU, were evaluated clinicopathologically.
RESULTS: Among 31 patients with PF, 22 had underlying systemic diseases such as collagen vascular diseases, while nine had unknown aetiology. Evidence of glomerulonephritis was demonstrated in 14 patients. The clinical features were a history of dry cough and/or fine crackles in all 31 patients. Chest CT scans showed honeycombing in the lung bases in 26 patients. The histopathological features of the diseased lung tissues in all 11 autopsied cases were compatible with the usual interstitial pneumonia (UIP) pattern. Vasculitis was confirmed in bronchial arteries and/or pulmonary arterioles in five patients. The mortality was as high as 13 of the 31 patients. The causes of death were: deterioration of PF in five (two of whom were associated with pulmonary haemorrhage), lung cancer in two, pneumonia in four, and digestive tract bleeding in two. The survival rates in PF with MPO-ANCA-negative collagen vascular diseases, cryptogenic fibrosing alveolitis (CFA), and PF with positive MPO-ANCA, were compared. The 5-year survival rate in PF with positive MPO-ANCA was worse than in PF with MPO-ANCA-negative collagen vascular diseases and was the same for CFA.
CONCLUSION: Although there was no correlation between MPO-ANCA titres and the activity of PF, this study demonstrated that the presence of positive MPO-ANCA was an unfavorable prognostic factor in patients with PF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182268     DOI: 10.1111/j.1440-1843.2004.00581.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  37 in total

1.  Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis.

Authors:  Misbah Baqir; Eunhee E Yi; Thomas V Colby; Christian W Cox; Jay H Ryu; Ulrich Specks
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 2.  Pulmonary Involvement in Systemic Vasculitis.

Authors:  Luis Felipe Flores-Suárez; Marco A Alba; Heidegger Mateos-Toledo; Natllely Ruiz
Journal:  Curr Rheumatol Rep       Date:  2017-09       Impact factor: 4.592

Review 3.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

4.  De novo myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated glomerulonephritis 31 years after living-donor kidney transplantation.

Authors:  Naoki Haruyama; Akihiro Tsuchimoto; Kosuke Masutani; Hideko Noguchi; Takaichi Suehiro; Hidehisa Kitada; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  CEN Case Rep       Date:  2014-07-30

5.  Microscopic polyangiitis associated with pulmonary fibrosis.

Authors:  Marcelo Fernandez Casares; Alejandra Gonzalez; Mariano Fielli; Flavia Caputo; Yanina Bottinelli; Marcelo Zamboni
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

6.  Scleroderma associated with ANCA-associated vasculitis.

Authors:  Young Hee Rho; Seong Jae Choi; Young Ho Lee; Jong Dae Ji; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2005-07-13       Impact factor: 2.631

7.  Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Gabrielle Y Liu; Iazsmin Bauer Ventura; Natalia Achtar-Zadeh; Brett M Elicker; Kirk D Jones; Paul J Wolters; Harold R Collard; Ayodeji Adegunsoye; Mary E Strek; Brett Ley
Journal:  Chest       Date:  2019-06-07       Impact factor: 9.410

8.  Elevated serum levels of two anti-neutrophil cytoplasmic antibodies in a lung cancer patient: A case report.

Authors:  Shinichiro Okauchi; Tomohiro Tamura; Katsunori Kagohashi; Mio Kawaguchi; Hiroaki Satoh
Journal:  Biomed Rep       Date:  2016-09-06

Review 9.  [Wegener's granulomatosis and microscopic polyangiitis].

Authors:  K de Groot; E Reinhold-Keller
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

10.  Pulmonary fibrosis-an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis?

Authors:  Amir Bhanji; Mahzuz Karim
Journal:  NDT Plus       Date:  2010-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.